Management of Combined CHF and CRF
Transcript of Management of Combined CHF and CRF
![Page 1: Management of Combined CHF and CRF](https://reader036.fdocument.pub/reader036/viewer/2022062418/556e6720d8b42a6a248b4f21/html5/thumbnails/1.jpg)
Management of Combined
CHF and CRFRi 王薏茜
2003-06-23
![Page 2: Management of Combined CHF and CRF](https://reader036.fdocument.pub/reader036/viewer/2022062418/556e6720d8b42a6a248b4f21/html5/thumbnails/2.jpg)
CRF ↔ CHF (1) Average SCr of CHF patient : 1.5 mg/dl Mortality of CHF patients
40% sudden death 40% worsening CHF 20% others
Cancer, COPD, infection…
![Page 3: Management of Combined CHF and CRF](https://reader036.fdocument.pub/reader036/viewer/2022062418/556e6720d8b42a6a248b4f21/html5/thumbnails/3.jpg)
CRF ↔ CHF (2) CV disease in CRF patients
At starting diaslysis 30-70% HTN 60% IHD 18-20% LVH 31-34% CHF
CVD mortality: 5-50x(10-30x) more than in normal population
Account for >50% of ESRD patient mortality
![Page 4: Management of Combined CHF and CRF](https://reader036.fdocument.pub/reader036/viewer/2022062418/556e6720d8b42a6a248b4f21/html5/thumbnails/4.jpg)
CRF ↔ CHF (3)
incidence CAD LVH CHF
General population 5-12 20 5
Dialysis 40 75 40
Renal transplant 15 50 -
CRF - 25-50 -
No/1000pts/year 20-44 45-64 >65
CV death 43 76 179
After transplant 3.1 7.7 -
![Page 5: Management of Combined CHF and CRF](https://reader036.fdocument.pub/reader036/viewer/2022062418/556e6720d8b42a6a248b4f21/html5/thumbnails/5.jpg)
Risk factors for CV diseases Normal population
Old age, male, race Hyperlipidemia Hypertension, DM homocysteinemia Physical inactivity Family history Menopause Socioeconomic stat
us Smoking Infectous agents
Related to uremia Hyper/hypo tension Anemia Low HDL, High LDL Hypertriglyceridemia Lp(a) Hyperparathyoidism Ca X P Uremic toxins Oxidative stress Impaired gibrinosysis Insulin resistance Hymocysteine Thrombogenic factors Endothelialdysfunction Chronic inflammation Carbonyl stress Sleep apnea
Related to dialysis Hyper/hypo tension Malnutrition Hypoalbuminemia Low body mass index Na water retention
![Page 6: Management of Combined CHF and CRF](https://reader036.fdocument.pub/reader036/viewer/2022062418/556e6720d8b42a6a248b4f21/html5/thumbnails/6.jpg)
HTN in ESRD Strongest risk factor of LV hypertrophy For SCr = 3.3 ± 1.1 mg/dl
Optimal BP: 3% High normal: 9% Stage 1 HTN (140-160): 34.4% Stage 2/3 HTN (160-200): 52.5%
Mortality vs hypertension: J-shaped
![Page 7: Management of Combined CHF and CRF](https://reader036.fdocument.pub/reader036/viewer/2022062418/556e6720d8b42a6a248b4f21/html5/thumbnails/7.jpg)
HTN in ESRD: mechanism Total sodium increase Plasma renin activity increase Noradrenergic hyperactivity Na/water retention AV fistula Anemia
![Page 8: Management of Combined CHF and CRF](https://reader036.fdocument.pub/reader036/viewer/2022062418/556e6720d8b42a6a248b4f21/html5/thumbnails/8.jpg)
Hypotention in ESRD? BP<110: 4x increase in mortality
Now suggested as a marker of ventricular systolic/diastolic dysfunction
![Page 9: Management of Combined CHF and CRF](https://reader036.fdocument.pub/reader036/viewer/2022062418/556e6720d8b42a6a248b4f21/html5/thumbnails/9.jpg)
IHD in ESRD At starting dialysis: 18-20% with IHD
Presentation Infarction: 56% Angina:82% CABG: 14% Angioplasyt: 1%
With IHD Without IHD
Progression to heart failure 24m 55m
Mean survival time 44m 56m
![Page 10: Management of Combined CHF and CRF](https://reader036.fdocument.pub/reader036/viewer/2022062418/556e6720d8b42a6a248b4f21/html5/thumbnails/10.jpg)
IHD in ESRD: risk factors Older age DM HTN Dyslipidemia Hypoalbuminemia Hyperhomocysteinemia:
83% of patients having levels higher than 90th percentile Associate with 7x increase in mortality
Lp(a)
![Page 11: Management of Combined CHF and CRF](https://reader036.fdocument.pub/reader036/viewer/2022062418/556e6720d8b42a6a248b4f21/html5/thumbnails/11.jpg)
LVH in ESRD Mechanism
Re-expression of fetel Growth Factor/GFR Myocyte death, fibroblast growth (ESRD>DM, HTN)
Interstitial fibrosis Diastolic dysfunction Intolerate to volume change (wall stiffness) Early reflection
arrhythmia Independent prognostic factor for survival !!
LVMI> 125 mg/m2: 25% (4-y) LVMI< 125 mg/m2: 55% LVEF<40%: odds ratio for mortality: 1.89
![Page 12: Management of Combined CHF and CRF](https://reader036.fdocument.pub/reader036/viewer/2022062418/556e6720d8b42a6a248b4f21/html5/thumbnails/12.jpg)
Survival in ESRD with/without LVH
![Page 13: Management of Combined CHF and CRF](https://reader036.fdocument.pub/reader036/viewer/2022062418/556e6720d8b42a6a248b4f21/html5/thumbnails/13.jpg)
LVH in ESRD : prevalence In early renal dz (CCr>30ml/min)
65% eccentric hypertrophy 16% concentric hypertrophy
In patients with CCr=10-30ml/min 26% concentric hypertrophy
In dialysis pts (CCr<10ml/min) 44% eccentric 42-50% concentric
![Page 14: Management of Combined CHF and CRF](https://reader036.fdocument.pub/reader036/viewer/2022062418/556e6720d8b42a6a248b4f21/html5/thumbnails/14.jpg)
LVH in ESRD: independent factors for LVH
Hypertention BP ↑ 5mmHg: LVMI ↑10g/m2
Male gender BMI >25 Hb <10-12
Hb ↓ 0.5 mg/dl: LVMI ↑10g/m2
![Page 15: Management of Combined CHF and CRF](https://reader036.fdocument.pub/reader036/viewer/2022062418/556e6720d8b42a6a248b4f21/html5/thumbnails/15.jpg)
LVH in ESRD: hemodynamic mechanism Volume overload
AV fistula Na/water retention Anemia
Pressure overload Aotic wall/ventricular wall stiffness Atherosclerosis RAS overactivity: ACEI
Dialysis: ∆ Ca(inotropic) and sympathetic tone
![Page 16: Management of Combined CHF and CRF](https://reader036.fdocument.pub/reader036/viewer/2022062418/556e6720d8b42a6a248b4f21/html5/thumbnails/16.jpg)
LVH in ESRD: role of anemia When Hb<10-12
Reactive hemodynamic change Stroke volume ↑ Heart rate ↑
Odds ratio for CRF =1.32 / 0.5 Hb ↓ Odds ratio for ESRD = 1.46 / 1 Hb ↓ EPO?
![Page 17: Management of Combined CHF and CRF](https://reader036.fdocument.pub/reader036/viewer/2022062418/556e6720d8b42a6a248b4f21/html5/thumbnails/17.jpg)
CHF in ESRD Epidemiology
In starting dialysis 31% with CHF 25% develop CHF later
Mortality 8.9% die of CHF/year
Survival
With CHF Without CHF
4-y survival 20% 60%
Mean suvival 36 months (29m/45m) 62 months
![Page 18: Management of Combined CHF and CRF](https://reader036.fdocument.pub/reader036/viewer/2022062418/556e6720d8b42a6a248b4f21/html5/thumbnails/18.jpg)
Survival in ESRD with/without CHF
![Page 19: Management of Combined CHF and CRF](https://reader036.fdocument.pub/reader036/viewer/2022062418/556e6720d8b42a6a248b4f21/html5/thumbnails/19.jpg)
CHF in ESRD: factors Factors related to onset:
Age DM Ischemic heart disease
Factors related to recurrence: Ischemic heart disease Anemia Hypoalbuminemia hypertension
![Page 20: Management of Combined CHF and CRF](https://reader036.fdocument.pub/reader036/viewer/2022062418/556e6720d8b42a6a248b4f21/html5/thumbnails/20.jpg)
D/D intrinsic myocardial dysfunction v.s. pure volume overload Echocardiography Radionuclide tecniques ANF and BNF(brain natriuretic factor):
Stress receptor in atriumrelease of ANF, BNF Stress receptor in ventriclerelease of BNF
NF receptors in kidney, adrenal glomerulose, vascular smooth muscle…
Na excretion, vasodilatation, renin/aldosterone ↓,… ANF: associated more with volume overload BNF: associated more with ventricular dysfunction
![Page 21: Management of Combined CHF and CRF](https://reader036.fdocument.pub/reader036/viewer/2022062418/556e6720d8b42a6a248b4f21/html5/thumbnails/21.jpg)
Management principles
Preventive intervention should be initiated early in the first year of dialysis.
Later treatment (CHF) has limited possibility of success.
![Page 22: Management of Combined CHF and CRF](https://reader036.fdocument.pub/reader036/viewer/2022062418/556e6720d8b42a6a248b4f21/html5/thumbnails/22.jpg)
Management principles Major goal: treating underlying factors predi
spose to heart failure HTN, DM, hyperPTH, dyslipidemia, anemia Treatment of hemodynamic overload
![Page 23: Management of Combined CHF and CRF](https://reader036.fdocument.pub/reader036/viewer/2022062418/556e6720d8b42a6a248b4f21/html5/thumbnails/23.jpg)
Pharmacologic therapy Diuretics
Higher dose/ combine thiazide/ IF continuous use Monitor K+, regular supplement
ACEI/Angiotensin Receptor Blockers: proven survival benefit, IHD↓,LVMI↓, GFR decline↓ If hyperkalemia/renal function↓: hydralizine + nitrate Side effect: anemia: EPO ↓, bone marrow ultilization of EPO↓
Beta-blocker: IHD, HTN, CHF Digoxin
Cleared by kidney, NOT removed by dialysis Impact on symptom, functional capacity, hospitalized frequency,
NOT on survival
![Page 24: Management of Combined CHF and CRF](https://reader036.fdocument.pub/reader036/viewer/2022062418/556e6720d8b42a6a248b4f21/html5/thumbnails/24.jpg)
Management: aggressive correction of anemia CRA syndrome: cardi
o-renal-anemia Anemia CHF
Damaged myocyte EPO production↓ Depress progenitor eryt
hrocyte in bone marrow Interfere with RE syste
m release of iron
![Page 25: Management of Combined CHF and CRF](https://reader036.fdocument.pub/reader036/viewer/2022062418/556e6720d8b42a6a248b4f21/html5/thumbnails/25.jpg)
Management: aggressive correction of anemia 50% of CHF patients have Hb<12 66-80% of class IV CHF pts have Hb<12 Clinical trial in 2001
126 pts: anemic, CHF treatmtne-resistant, NYHA class 3-4
Target goal: keep Hb = 12.5-13 for 12.4 ± 8.2 m Mean:
EPO 4000-5000 u if Hb<12.5 Keep serum ferritin>500ug/L, Sat>40%
![Page 26: Management of Combined CHF and CRF](https://reader036.fdocument.pub/reader036/viewer/2022062418/556e6720d8b42a6a248b4f21/html5/thumbnails/26.jpg)
Management: aggressive correction of anemia
1-year Mortality in:
Class 3-4 CHF patients: 30-50%
This trial: 7.1%
![Page 27: Management of Combined CHF and CRF](https://reader036.fdocument.pub/reader036/viewer/2022062418/556e6720d8b42a6a248b4f21/html5/thumbnails/27.jpg)
Management: intensive volume control
Basis LVH accounts for large No of mortality in ESRD sBP elevation is the strongest risk factor for LVH Regression of LVH with BP control is well establi
shed Difficulty in controlling BP in ESRD pts, may be d
ue to hidden volume expansion, which is out of reach of antihypertensive medications.
![Page 28: Management of Combined CHF and CRF](https://reader036.fdocument.pub/reader036/viewer/2022062418/556e6720d8b42a6a248b4f21/html5/thumbnails/28.jpg)
Management: intensive volume control
Effect of intensive hemodialysis on BP control
Mean: 12h H/D per week, without antihypertensive drug As much UF as possible, without excess BP drop Dietary salt restriction 3 months of intensive volume control 12 months of follow up
![Page 29: Management of Combined CHF and CRF](https://reader036.fdocument.pub/reader036/viewer/2022062418/556e6720d8b42a6a248b4f21/html5/thumbnails/29.jpg)
Management: intensive volume control
Avoid rapid volume shift Maintaining a low dry weight Regression of LVH, LVD, LV stiffness
sPB dBP BW CTI LA EDD ESD LVMI %LVH
Htc
Pre-HD 168 97 63.3 48 - - - - - 29.5
Post-HD(3ms)
127 78 60.3 46 24.3 29.3 18.8 164 63 33.7
6ms 120 75 62.4 44 22.6 26.7 17.3 121 32 34.2
12ms 118 73 65.4 43 22.6 26.4 18.0 112 18 33.2
![Page 30: Management of Combined CHF and CRF](https://reader036.fdocument.pub/reader036/viewer/2022062418/556e6720d8b42a6a248b4f21/html5/thumbnails/30.jpg)
Conclusion CRF patients have a very high risk of develop CV
D: HTN, LVH, IHD, CHF Account for more than 50% of ESRD patient mortality
Management: risk reduction: anemia, BP control, volume management, medication toward symptoms: diuretics, digoxin, ACEI/AR
Bs, beta-blockers, correct dyslipidemia Proper dialysis Early intervention!
![Page 31: Management of Combined CHF and CRF](https://reader036.fdocument.pub/reader036/viewer/2022062418/556e6720d8b42a6a248b4f21/html5/thumbnails/31.jpg)
Reference Seminars in dialysis 2003 vol 16(2):85-94 J of Nephrology 2002 15:655-60 Clinical nephrology 2002 vol 58 (supple1):s37-45 Ame J of Kidney diseases 2001 vol 38(4, supple
1):s38-46 Peritoneal dialysis international. 2001 Vol 21(S3):
s236-9 Seminars in nephrology. 2001 vol 21 (1):3-12
![Page 32: Management of Combined CHF and CRF](https://reader036.fdocument.pub/reader036/viewer/2022062418/556e6720d8b42a6a248b4f21/html5/thumbnails/32.jpg)
Thank you for your attention !